Novo Holdings looks to boost life sciences investments

Prescription Drugs and Money image
Novo Nodisk's venture capital arm is focusing on biotechs in the U.S. and Europe. (

Novo Holdings says it is looking to fuel more early- and late-stage biotechs. The venture capital firm said that, over the next few years, it is plotting to “increase its investments in life science companies at all stages of development: from seed companies in the early phases to well-established, cash-generative companies,” with a focus on those in the U.S. and Europe.

“We see a long-term positive trend for the life science industry and expect to continue increasing our investments in the coming years. The positive returns from our portfolio of life science investments and several successful exits and IPOs in recent years reinforce our optimism,” said Kasim Kutay, the firm’s CEO.

The data come from its annual review (PDF) posted this morning.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Looking at the balance sheet, Novo Holdings saw income and investment returns of DKK 20.7 billion ($3.5 billion) last year, with the return from life science investments outside the Novo Group providing more than half the profit.

RELATED: Novo Holdings ponies up $165M for superbug venture fund

It made new investments in the sector worth DKK 13.9 billion in 2017, with the investments in German companies Evotec and Synlab, as well as in British company ConvaTec, accounting for just over DKK 11 billion of the new investment total. On the venture front, Novo Holdings invested in 12 new companies and exited 14 others.

“We executed in accordance with our strategy and invested with a long-term perspective. We are satisfied with the result, and our return on life science investments now stands at 21% for the past five years and 18% over 10-years on an annual basis,” says Kutay.

The firm is the holding company in the Novo Group, comprising of biopharma Novo Nordisk, as well as Novozymes and NNIT, and is responsible for managing the Foundation’s assets. 

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.